Clinical Trials Browser

EGFR Mutated EGFR TKI Naive Metastatic NSCLC × N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all

NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

EGFR Mutated EGFR TKI Naive Metastatic NSCLC